Ken Griffin Adicet Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2025 May 15, 2025	SELL	$0.76 - $1.09 $9,272 - $13,298	-12,200 Reduced 42.51%	16,500 $12,000
Q4 2024 Feb 14, 2025	BUY	$0.86 - $1.52 $18,920 - $33,440	22,000 Added 328.36%	28,700 $27,000
Q3 2024 Nov 14, 2024	SELL	$1.07 - $1.63 $5,457 - $8,313	-5,100 Reduced 43.22%	6,700 $9,000
Q2 2024 Aug 14, 2024	BUY	$1.21 - $2.4 $6,655 - $13,200	5,500 Added 87.3%	11,800 $14,000
Q1 2024 May 15, 2024	SELL	$1.76 - $3.45 $19,536 - $38,295	-11,100 Reduced 63.79%	6,300 $14,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $1.89 $3,663 - $6,237	-3,300 Reduced 15.94%	17,400 $32,000
Q3 2023 Nov 14, 2023	BUY	$1.37 - $3.4 $8,631 - $21,420	6,300 Added 43.75%	20,700 $28,000
Q2 2023 Aug 14, 2023	SELL	$2.13 - $7.13 $4,686 - $15,686	-2,200 Reduced 13.25%	14,400 $34,000
Q1 2023 May 15, 2023	BUY	$5.52 - $9.23 $30,359 - $50,765	5,500 Added 49.55%	16,600 $95,000
Q4 2022 Feb 14, 2023	SELL	$7.72 - $21.27 $108,852 - $299,907	-14,100 Reduced 55.95%	11,100 $99,000
Q3 2022 Nov 14, 2022	BUY	$13.43 - $18.74 $338,436 - $472,247	25,200 New	25,200 $358,000

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $31.2M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.